| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.9 |